Today's Rundown Boehringer buys oncolytic virus startup ViraTherapeutics Is Moderna prepping for biotech's biggest-ever IPO? Half of European studies fail to report results: BMJ report Gilead taps gene editors at Precision BioSciences for hepatitis B cure development AbbVie builds case for potential psoriasis blockbuster risankizumab ahead of regulatory decisions Surface’s Biniszkiewicz, Chappel join MPM Capital as executive partners VistaGen nabs phase 3-ready social anxiety drug from Pherin New Apple Watch receives FDA clearance for built-in ECG Featured Story | | | Thursday, September 13, 2018 Boehringer Ingelheim has bought oncolytic virus startup ViraTherapeutics. The takeover is focused on vesicular stomatitis virus candidates Boehringer sees becoming key components of its efforts to gain ground in the immuno-oncology sector. |
|
|
| This week's sponsor is Synteract, Inc. | | | |
Top Stories Thursday, September 13, 2018 Already cash-rich, Moderna Therapeutics is said to be planning an initial public offering to extend its resources even further and advance development of its mRNA-based drugs. Thursday, September 13, 2018 New research out by the BMJ shows that half of tracked clinical trials across Europe “have not reported trials,” but biopharmas are doing much better than their academic peers when it comes to disclosing data. Thursday, September 13, 2018 Gilead Sciences is pursuing a new avenue toward hepatitis B treatment, collaborating on gene therapies aimed at eliminating viral infections in vivo by using Precision BioSciences’ genome editing platform. Thursday, September 13, 2018 AbbVie has posted an analysis of patient-reported outcomes from phase 3 trials of risankizumab. The analysis builds out the evidence in support of the IL-23 antibody ahead of anticipated approvals that will clear it to duke it out for the psoriasis market. Thursday, September 13, 2018 Surface Oncology’s Detlev Biniszkiewicz, Ph.D., and Scott Chappel, Ph.D., have both made the jump to MPM Capital as executive partners. They will help identify and oversee new investment opportunities in oncology startups and take on leadership roles in those companies. Thursday, September 13, 2018 VistaGen Therapeutics has licensed Pherin Pharmaceuticals' lead candidate, a nasal spray for social anxiety disorder. Wednesday, September 12, 2018 The latest iteration of Apple’s smartwatch includes an FDA-cleared electrocardiogram, officially classifying it as a medical device capable of alerting its user to abnormal heart rhythms. Resources Sponsored by: Veeva A top 20 pharma and growing biotech re-engineer regulatory processes. Sponsored by: Sciformix Are automation, big data and artificial intelligence (AI) a key part of your company’s pharmacovigilance strategy? Read this whitepaper to know what they should be! Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. Sponsored by: Patheon, part of Thermo Fisher Scientific When developing a parenteral, pharmaceutical scientists are faced with a variety of choices – choices that can be conflicting or present differing advantages. Sponsored by: Baxter Baxter BioPharma Solutions’ whitepaper offers a method to address the challenges of tech transfer for lyophilized products from lab-scale to commercial-scale. Sponsored by: Catalent In this case study, an unknown leachable species was detected by GC-MS analysis of an alkaline drug product (pH approximately 10.5) that was packaged in a novel self- contained plastic Blow Fill Seal (BFS) vial. Sponsored by: Blue Matter A whitepaper outlining the key commercial challenges facing rare disease products, and how biopharmaceutical companies can overcome them. Sponsored by: AWS and Tableau Inova is using the capabilities of Tableau on AWS to identify biomarkers for personalized treatment intended to improve health outcomes for children. Sponsored by: Catalent Catalent provides world class stability services to ease your critical path to success. Sponsored by: AWS and Reltio Reltio and IQVIA provide holistic data management solutions for traditional pharma, emerging biotech, and consumer health companies, on AWS. Presented by: AWS and Druva Life Sciences organizations are embracing cloud-based Master Data Management (MDM) to modernize the organization of critical data. Sponsored by: Health Strategies Group The window of market exclusivity continues to narrow dramatically in the global marketplace. Given this demanding environment, your global market access team faces increasing urgency to get the value proposition right at the time of launch. Drug Approval, Manufacturing Quality & Regulation 2018 | Online Drug Development Boot Camp® 2018 – Registration closes 30 October - Register Now! November 14-15, 2018 | Boston, MA | Registration closes on the 30 of October 2018 due to the need for participants to complete pre-Boot Camp preparations. Register now and start preparing for this intensive training in drug development. 2018 Latin America Healthcare Compliance Certification Program September 24-27, 2018 | Sao Paulo, Brazil Drug Development Immersion September 26-27, 2018 | West Windsor, NJ FierceBiotech 3rd Drug Development Forum October 1–3, 2018 | Hilton Boston Logan Airport Hotel | Boston, MA Compliance Certification Program at Seton Hall Law October 8-11, 2018 | Newark, NJ BioImmersion: Biotech for the Non-Scientist October 16-18, 2018 | Chicago, IL Fierce Innovation Awards: Life Sciences Edition 2018 FierceBiotech Executive Summit: London October 30, 2018 | Royal Society of Medicine Understanding Commercialization Within Biopharma Nov 7-8, 2018 | Boston, MA Drug Development Boot Camp® 2018 – Register Now! November 14-15, 2018 | Boston, MA | Register now and start your pre-Boot Camp preparation Drug Development Immersion December 5-6, 2018 | San Diego, CA Understanding Drug Pricing and Reimbursement December 12, 2018 | Boston, MA | 